onasemnogen abeparvovec

Ukraine

Drugs containing this active substance

  • ZOLGENSMA

    The drug is intended for gene therapy in children up to 2 years of age with spinal muscular atrophy (SMA) caused by mutations in the SMN1 gene.

    Form: suspension, for intravenous infusion

    Active substance Dosage
    onasemnogen abeparvovec 2 x 10^13 vg/ml

    ATC: M09AX09

    Manufacturer: Novartis Gene Therapies, Inc. (manufacturing, primary packaging, partial quality control, secondary packaging, batch release)